Thalys(SH:603716)2025-01-17 09:10Financial Performance - The company expects a net profit attributable to shareholders for 2024 to be between -210 million RMB and -250 million RMB, representing an increase in losses of 51.43 million RMB to 91.43 million RMB year-on-year [4]. - The expected net profit attributable to shareholders after deducting non-recurring gains and losses for 2024 is projected to be between -145 million RMB and -190 million RMB, with a year-on-year change indicating a decrease in losses of 15.57 million RMB to an increase of 29.43 million RMB [5]. - The company's total profit for 2023 was -192.50 million RMB, with a net profit attributable to shareholders of -158.57 million RMB [6]. Business Operations - The company transferred 80% equity of Wuhan Huixin Technology Development Co., Ltd. and 51% equity of Aksu Yonglin Ruifu Electronic Technology Co., Ltd., resulting in a loss of approximately 60 million RMB [7]. - The company's operating revenue has decreased due to the expiration of certain contracts in the in vitro diagnostics business and the impact of industry policies, leading to a decline in both revenue and profit compared to the previous year [8]. Research and Development - The company has increased investment in the research and development of in vitro diagnostic reagents and smart medical IoT applications, resulting in higher R&D costs [9]. Impairment and Valuation - The company has recognized impairment of goodwill due to a decline in revenue and profit from certain subsidiaries [10]. - The company is currently assessing the value of goodwill and long-term equity investments, with results yet to be determined [12]. Performance Forecast - The company has not identified any significant uncertainties that may affect the accuracy of this performance forecast [13].